Investment Summary

EW Healthcare Partners Invests In Metabolon

On August 11, 2016, growth capital firm EW Healthcare Partners invested in life science company Metabolon for 15M USD

Investment Highlights
  • This is EW Healthcare Partners’ 15th transaction in the Life Science sector.
  • This is EW Healthcare Partners’ 2nd largest (disclosed) transaction.
  • This is EW Healthcare Partners’ 45th transaction in the United States.
  • This is EW Healthcare Partners’ 3rd transaction in North Carolina.

Investment Summary
Date 2016-08-11
Target Metabolon
Sector Life Science
Investor(s) EW Healthcare Partners
Deal Type Growth Capital
Deal Value 15M USD

Target

Metabolon

Morrisville, North Carolina, United States
Metabolon is a health technology company focused on the use of metabolomics in precision medicine. Metabolon’s expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. Metabolon was founded in 2000 and is based in Morrisville, North Carolina.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

EW Healthcare Partners

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1985
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.

DEAL STATS #
Overall 50 of 59
Sector (Life Science) 15 of 20
Type (Growth Capital) 7 of 10
State (North Carolina) 3 of 3
Country (United States) 45 of 50
Year (2016) 1 of 2
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-17 Open Monoclonal Technology

Palo Alto, California, United States

Open Monoclonal Technology, Inc. (OMT) is a biotechnological company provides genetic engineering of animals for discovery of human therapeutic antibodies, naturally optimized human antibodies® and the only company with three transgenic animal platforms, collectively known as OmniAb™. All OmniAb platforms — OmniRat®, OmniMouse®, and OmniFlic™ — have broad freedom to operate, are protected by new patents and patent applications, and are available for all targets and indications

Sell $178M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-12-20 Cota

New York, New Jersey, United States

Cota, Inc. is a provider of health care informatics and precision analytics company that builds research-grade, real-world data to exponentially improve outcomes, reduce cost and ensure the right care for the right patient every time. Cota was founded in 2011 and is based in New York City.

Buy -
Mergr

Product

Company

Legal